Enlivex Therapeutics Ltd. (ENLV) Ownership
ENLV ownership summary
as of October 18, 2026- Institutions
- 1.4% of shares outstanding
- Insiders
- 68.82% of shares outstanding
- Shares outstanding
- 19.9M
- Float
- 6.5M shares available to trade
- Short interest
- 0.50% 99K shares short
- Days to cover
- 0.22 short interest up 104.5% vs prior month
- Institutions 1.42%
- Insiders 68.82%
- Other investors 29.75%
ENLV top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | ARK Investment Management LLC | 0.80% | 2.4M | $488,460 | +1.8M (+279.2%) | June 30, 2026 |
| 2 | Springbok Capital Management, LLC | 0.11% | 321K | $65,868 | +95,568 (+42.3%) | June 30, 2026 |
| 3 | Bank of America Corp | 0.06% | 193K | $39,596 | +62,749 (+48.1%) | June 30, 2026 |
| 4 | Two Sigma Investments LLC | 0.06% | 184K | $37,704 | +37,512 (+25.6%) | June 30, 2026 |
| 5 | Susquehanna International Group, LLP | 0.05% | 158K | $32,318 | +147,334 (+1,428.5%) | June 30, 2026 |
| 6 | Renaissance Technologies Corp | 0.04% | 134K | $27,450 | +5,708 (+4.5%) | June 30, 2026 |
| 7 | Geode Capital Management, LLC | 0.04% | 130K | $26,621 | +49,298 (+61.2%) | June 30, 2026 |
| 8 | JPMorgan Chase & Co | 0.04% | 121K | $24,866 | −4,652 (−3.7%) | June 30, 2026 |
| 9 | SIMPLEX TRADING, LLC | 0.04% | 111K | $22,838 | +108,791 (+4,160.3%) | June 30, 2026 |
| 10 | The Goldman Sachs Group Inc | 0.03% | 89K | $18,330 | −12,676 (−12.4%) | June 30, 2026 |
| 11 | UBS Group AG | 0.02% | 74K | $15,151 | −64,419 (−46.6%) | June 30, 2026 |
| 12 | HRT FINANCIAL LLC | 0.02% | 50K | $10,180 | +49,657 (0.0%) | June 30, 2026 |
| 13 | XTX Topco Ltd | 0.01% | 22K | $4,485 | −78,486 (−78.2%) | June 30, 2026 |
| 14 | Morgan Stanley - Brokerage Accounts | <0.01% | 8,497 | $1,742 | −89,836 (−91.4%) | June 30, 2026 |
| 15 | MCGUIRE CAPITAL ADVISORS INC | <0.01% | 2,500 | $512 | — | June 30, 2026 |
| 16 | Group One Trading, LLC | <0.01% | 1,042 | $214 | +835 (+403.4%) | June 30, 2026 |
| 17 | Activest Wealth Management | <0.01% | 1,000 | $205 | — | June 30, 2026 |
| 18 | Steward Partners Investment Advisory, LLC | <0.01% | 500 | $102 | — | June 30, 2026 |
| 19 | Advisor Group Holdings, Inc. | <0.01% | 402 | $82 | −770 (−65.7%) | June 30, 2026 |
| 20 | Red Tortoise LLC | <0.01% | 150 | $31 | — | March 31, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 10 holders added 2.3M shares and 6 cut 251K.
ENLV top mutual fund and ETF holders
1 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Fidelity Nasdaq Composite Index | 0.05% | 8,657 | $1,775 | −1 (−0.0%) | July 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
ENLV shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns ENLV
Institutional investors own 1.4% of Enlivex Therapeutics's shares and insiders 68.82%. The largest holder is ARK Investment Management LLC with 0.80% of the shares (2.4M), as of June 30, 2026. Among the top 20 institutions, 10 added shares and 6 reduced their stake in the latest filings. Short interest is 0.50% of the float, or 0.22 days of average trading volume. The share count rose 13,457.8% since 2014.
Related: ENLV analyst forecast, ENLV key metrics. See the ENLV stock overview for the latest quote and news.
ENLV ownership FAQ
Who owns the most Enlivex Therapeutics stock?
The largest shareholders of Enlivex Therapeutics are ARK Investment Management LLC (0.80%), Springbok Capital Management, LLC (0.11%), Bank of America Corp (0.06%), Two Sigma Investments LLC (0.06%), Susquehanna International Group, LLP (0.05%).
What percentage of Enlivex Therapeutics is owned by institutions?
Institutions hold 1.4% of Enlivex Therapeutics's shares outstanding; insiders hold 68.82%.
Which funds own Enlivex Therapeutics?
The largest fund holders of Enlivex Therapeutics are Fidelity Nasdaq Composite Index (0.05%).
What is Enlivex Therapeutics's short interest?
99K shares of Enlivex Therapeutics were sold short, 0.50% of the float; at the average daily volume it would take 0.22 days to cover.
How many shares of Enlivex Therapeutics are outstanding?
Enlivex Therapeutics has 19.9M shares outstanding, of which 6.5M are in the public float.